GC Biopharma Corp. (KRX:006280)
South Korea
· Delayed Price · Currency is KRW 131,400
-1,000 (-0.76%)
Feb 20, 2025, 9:00 AM KST
GC Biopharma Revenue
GC Biopharma had revenue of 464.87B KRW in the quarter ending September 30, 2024, with 5.81% growth. This brings the company's revenue in the last twelve months to 1.64T, up 0.66% year-over-year. In the year 2023, GC Biopharma had annual revenue of 1.63T, down -4.95%.
Revenue (ttm)
1,643.98B
Revenue Growth
+0.66%
P/S Ratio
0.93
Revenue / Employee
818.31M
Employees
2,009
Market Cap
1,521.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1,626.64B | -84.67B | -4.95% |
| Dec 31, 2022 | 1,711.31B | 173.49B | 11.28% |
| Dec 31, 2021 | 1,537.83B | 33.71B | 2.24% |
| Dec 31, 2020 | 1,504.12B | 147.00B | 10.83% |
| Dec 31, 2019 | 1,357.12B | 22.24B | 1.67% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,364.39B |
| Celltrion | 2,876.25B |
| Yuhan | 2,008.84B |
| SK Biopharmaceuticals | 511.33B |
| SK bioscience | 201.30B |
| Hanmi Pharm. | 1,495.50B |
| Hanmi Science | 1,283.65B |
| Hanall Biopharma | 134.24B |